For many women, a diagnosis of herpes simplex virus (HSV) during pregnancy can trigger immediate anxiety. While the virus is one of the most common sexually transmitted infections globally, its implications change significantly during gestation, shifting from a manageable skin condition to a critical factor in fetal and neonatal health.
The primary concern for obstetricians and expectant mothers is the risk of vertical transmission—the passage of the virus from mother to child. While most cases of neonatal herpes are preventable, the timing and nature of the maternal infection dictate the level of risk. A primary infection acquired late in pregnancy, particularly in the final six weeks, presents the highest danger because the mother has not yet developed the neutralizing antibodies necessary to protect the newborn.
Medical evidence indicates that the maternal immune system undergoes a natural process of immunomodulation during pregnancy. This adaptation allows the body to tolerate the fetus, but it also reduces the effectiveness of the cellular responses that typically keep the herpes virus in a latent, inactive state. This biological shift can trigger viral reactivation or make a new infection more severe, potentially leading to adverse perinatal outcomes including spontaneous abortion, stillbirth, and preterm birth.
Understanding the maternal–fetal implications of herpes virus infection requires a distinction between the different ways a newborn can be exposed. While transplacental transmission is rare—occurring in roughly 5% of neonatal cases—the vast majority of infections occur during the intrapartum period, as the infant passes through a birth canal contaminated with maternal secretions.
The Spectrum of Neonatal Infection
When a newborn is infected with HSV, the clinical manifestations generally fall into three categories, varying widely in severity and prognosis. The most common form, affecting up to 85% of infected neonates, is Skin-Eye-Mouth (SEM) disease. This typically presents as clustered vesicles or ocular inflammation and, while often considered the most benign form, can still result in permanent ocular impairment if left untreated.
More critical are infections localized to the central nervous system (CNS), which may manifest as lethargy, irritability, or seizures up to six weeks of life. The most severe is disseminated disease, occurring in approximately 25% of infected neonates. This form involves multiple organ systems, including the liver, lungs, and brain, and is most frequently seen in preterm infants or those born to mothers with a primary infection.
The severity of these outcomes is often tied to the presence of maternal IgG antibodies. These proteins cross the placenta starting around the 13th week of gestation, providing a layer of passive immunity. In cases where the mother is seronegative or acquires the virus too late to produce these antibodies, the newborn is left vulnerable to the most aggressive forms of the disease.
Clinical Management and Delivery Planning
The goal of obstetric management is to reduce viral shedding and prevent outbreaks at the time of delivery. For women with a history of genital herpes, clinicians typically recommend suppressive antiviral therapy starting at the 36th week of pregnancy. This regimen is designed to minimize the likelihood of active lesions during labor, which in turn reduces the require for emergency surgical interventions.
Acyclovir remains the gold standard for treatment due to its established safety profile across all trimesters. While valacyclovir is often used for its simpler dosing and higher bioavailability, both are effective at reducing the viral load. In the event of a primary infection in the third trimester, continuous treatment until birth is often considered to mitigate the high risk of transmission.
The decision regarding the mode of delivery is based strictly on the clinical presentation at the time of birth. According to guidelines from the American College of Obstetricians and Gynecologists (ACOG), a cesarean section is indicated if the mother has active genital lesions or prodromal symptoms, such as tingling or burning, at the onset of labor. Yet, a history of herpes without active lesions is not a mandatory indication for a C-section, as the risks of surgery may outweigh the benefits in those cases.
Comparative Risk by Infection Type
| Infection Type | Transmission Risk | Recommended Delivery | Key Management |
|---|---|---|---|
| Primary (3rd Trimester) | High (30–50%) | C-section if active lesions | Immediate antivirals |
| Recurrent Episode | Low | Vaginal (if no lesions) | Suppressive therapy (36w+) |
| Asymptomatic Shedding | Moderate/Low | Vaginal (if no lesions) | Clinical monitoring |
Prevention and Future Perspectives
Beyond medication, behavioral interventions play a critical role in protecting seronegative pregnant women. In serodiscordant couples—where the partner is positive for HSV—healthcare providers recommend selective abstinence during the partner’s symptomatic periods and the consistent use of condoms to prevent primary maternal infection during the high-risk third trimester.
Despite the prevalence of the virus, universal serologic screening for all pregnant women remains a point of contention. Currently, the CDC and ACOG do not recommend routine testing for asymptomatic women, citing a lack of evidence that such screening significantly reduces the incidence of neonatal herpes, alongside the potential for unnecessary emotional distress.
The long-term goal for public health is the development of an effective HSV vaccine. While several phase 3 trials over the last two decades have tested glycoproteins to prevent genital disease, they have largely failed to meet their primary objectives. Current research has shifted toward inactivated vaccines, live attenuated versions, and nucleic acid-based candidates to provide more robust protection before women reach reproductive age.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Please consult a qualified healthcare provider for diagnosis and treatment options.
As molecular diagnostics evolve, the use of highly sensitive PCR-based assays is expected to improve the detection of subclinical shedding, potentially refining the timing of suppressive therapies and improving neonatal prognoses. The next major checkpoint in this field will be the progression of new vaccine candidates through clinical trials, aiming to eliminate primary infection as a risk factor in pregnancy.
We invite readers to share their experiences with prenatal care and antiviral management in the comments below.
